Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA profiling in paired human prostate cancer and benign prostate tissue

ABSTRACT: To determine the altered microRNA expression signature in human prostate cancer compared to benign prostate tissue. To determine the altered mRNA expression signatures upon overexrpession miR-31 in prostate cancer cells.

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE36802 | GEO | 2013/02/05

SECONDARY ACCESSION(S): PRJNA156859

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

microRNA profiling in paired human prostate cancer and benign prostate tissue

Project description:To determine the altered microRNA expression signature in human prostate cancer compared to benign prostate tissue. To determine the altered mRNA expression signatures upon overexrpession miR-31 in prostate cancer cells. Two condition experiments:1) Total RNA from 21 pairs of prostate cancers and matched benign prostate tissues were collected and processed for microRNA detection. 2) In LNCaP prostate cancer cells, miR-31 was overexpressed and compared to control miR-NC.

2013-02-05 | E-GEOD-36802 | biostudies-arrayexpress

mRNA profiling of LNCaP cells treated with miR-31

2013-02-05 | GSE36801 | GEO

mRNA profiling of LNCaP cells treated with miR-31

2013-02-05 | E-GEOD-36801 | biostudies-arrayexpress

Serum proteomics in prostate cancer patients vs. healthy and benign prostate hyperplasia

Project description:The study aim was to identify novel serum markers of prostate cancer diagnosis compared to benign prostate hyperplasia and healthy controls

2016-10-04 | PXD004575 | Pride

Illumina M450 profiling of human prostate cancer tissue and benign prostate tissue

Project description:Illumina M450 profiling was conducted on clinically-annotated human prostate cancer tissue and benign prostate tissue

2017-04-10 | GSE76938 | GEO

Gene expression in benign and prostate cancer tissue

Project description:Benign prostate tissue and prostate cancer tissue (untreated, androgen deprivation therapy responding, or castrate-resistant) was collected from patients at the time of transurethral resection of the prostate surgery.

2012-12-01 | GSE28680 | GEO

Gene expression in benign and prostate cancer tissue

2012-12-01 | E-GEOD-28680 | biostudies-arrayexpress

Transcription profiling by array of human benign prostate, primary and metastatic prostate cancer samples to reveal signatures of metastatic progression

Project description:An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed revealing only 48-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors. Keywords: prostate cancer progression 13 individual benign prostate, primary and metastatic prostate cancer samples and 6 pooled samples from benign,primary or metastatic prostate cancer tissues.

2005-09-20 | E-GEOD-3325 | biostudies-arrayexpress

miRNA expression differences in tumor and benign prostate tissues

Project description:We investigated the global miRNA expression in prostate tumor and benign tissues by qPCR expression profiling.

2014-12-08 | GSE54516 | GEO

Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia

Project description:Although an increased level of the prostate-specific antigen can be an indication for prostate cancer, other reasons often lead to a high rate of false positive results. Therefore, an additional serological screening of autoantibodies in patients’ sera could improve the detection of prostate cancer. We performed protein macroarray screening with sera from 49 prostate cancer patients, 70 patients with benign prostatic hyperplasia and 28 healthy controls and compared the autoimmune response in those groups. We were able to distinguish prostate cancer patients from normal controls with an accuracy of 83.2%, patients with benign prostatic hyperplasia from normal controls with an accuracy of 86.0% and prostate cancer patients from patients with benign prostatic hyperplasia with an accuracy of 70.3%. Combining seroreactivity pattern with a PSA level of higher than 4.0 ng/ml this classification could be improved to an accuracy of 84.1%. For selected proteins we were able to confirm the differential expression by using Lluminex on 84 samples. We provide a minimally invasive serological method to reduce false positive results in detection of prostate cancer and according to PSA screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.

2017-02-10 | GSE67068 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data